Basic Information
Skilarence
Regulatory Information
EMEA/H/C/002157
Authorised
June 23, 2017
April 21, 2017
13
August 29, 2024
Company Information
Spain
Ronda General Mitre 151 08022 Barcelona
ALMIRALL SA
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Skilarence is indicated for the treatment of moderate to severe plaque psoriasis in adults in need of systemic medicinal therapy.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Skilarence. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Skilarence. For practical information about using Skilarence, patients should read the package leaflet or contact their doctor or pharmacist.